Comparing the current results to its competitors, Ayala Pharmaceuticals Inc reported Revenue decrease in the 4 quarter 2021 year on year by 0 %, despite the revenue increase by the most of its competitors of 22.32 %, recorded in the same quarter.
Ayala Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 70.15 %
Ayala Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The biotechnology and biopharmaceutical industries are characterized by competition from both biotechnology firms and major pharmaceutical companies. Notable competitors include AstraZeneca, BioNtech, BMS, Gritstone, Merck, Moderna, and Neon Therapeutics, all engaged in developing cancer vaccines and immunotherapies. Additional competition arises from universities, research institutions, and investigational new drugs developed through alternative technologies. Competitive factors encompass potential drug indications, timing of market introduction, development speed, clinical testing, regulatory approval, and manufacturing capacity. Approved products compete based on efficacy, safety, administration, reliability, market acceptance, availability, pricing, and patent status.
February 20, 2024
Immunome Recognizes Completion of Patient Enrollment in Ayala Pharmaceuticals Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsBOTHELL, Wash. - Immunome, Inc. recently acknowledged the announcement made by Ayala Pharmaceuticals, Inc. regarding the completion of patient enrollment in the Phase 3 RINGSIDE study. The study aims to evaluate the efficacy of AL102, a targeted cancer therapy, in patients with desmoid tumors. This development comes after Immunome s recent asset purchase agreement with Ayala Pharmaceuticals.Desmoid tumors are a rare type of tumor that arise from connective tissues, typically in the arms, legs, or trunk. They can be locally aggressive and fibrous, often causing pain and disfi...
Publicly Traded Peers of Ayala Pharmaceuticals Inc
Gilead Sciences Inc Share Performance
+23.14%
This Quarter
Gilead Sciences Inc
Profile
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Kazia Therapeutics Limited is a biotechnology company that focuses on developing and commercializing innovative oncology therapies. Their business model revolves around advancing novel drug candidates, conducting clinical trials, and collaborating with partners to bring their products to market.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Sources:
Ayala Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ayala Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
